US OptionsDetailed Quotes
LXRX250117C1000
- 0.05
- 0.000.00%
15min DelayClose Jan 13 16:00 ET
0.00High0.00Low
0.05Open0.05Pre Close0 Volume2.75K Open Interest1.00Strike Price0.00Turnover443.13%IV48.94%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.3012Delta1.0667Gamma14.12Leverage Ratio-0.0147Theta0.0000Rho4.25Eff Leverage0.0003Vega
Lexicon Pharmaceuticals Stock Discussion
Sign in to post a comment
$Lexicon Pharmaceuticals (LXRX.US)$
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)
Lexicon Pharmaceuticals (LXRX) has received a Complete Response Letter (CRL) from the FDA regarding its New Drug Application for Zynquista™ (sotagliflozin). The drug was intended as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes and chronic kidney disease (CKD). This decision was anticipated, aligning with Lexicon's previous s...
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)
Lexicon Pharmaceuticals (LXRX) has received a Complete Response Letter (CRL) from the FDA regarding its New Drug Application for Zynquista™ (sotagliflozin). The drug was intended as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes and chronic kidney disease (CKD). This decision was anticipated, aligning with Lexicon's previous s...
1
6
$Lexicon Pharmaceuticals (LXRX.US)$
come on fdaaaaaaaaaa
come on fdaaaaaaaaaa
1
1
$Lexicon Pharmaceuticals (LXRX.US)$ let see if it will still run after release of good news. Investors losing confidence.
2
$Lexicon Pharmaceuticals (LXRX.US)$ Tomorrow they get a second at bat for FDA approval! Last go round they were issued a CRL! Well here we are quite a ways removed from that first PDUFA calendar date! IMO since this is a redo. Hehehe! IMO that does make a ( NORMALLY ) bit better odds of a approval! But in this case at the pre meeting it didn’t look very positive! Also the answer can come anytime between tomorrow/Friday all the way to Monday!
4
8
1
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
NOTE!
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits
5. Always remember shorts include dark pools.
6. Most importantly, don’t blame for your losses. I already give watchlist and stock education. The ball is on you.
7. I DO NOT give buy or sell advice
8. COH (cash on hand); AH (after hours): RTH (regular trading hours)
$Aadi Biosciences (AADI.US)$ PR AH 12/...
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits
5. Always remember shorts include dark pools.
6. Most importantly, don’t blame for your losses. I already give watchlist and stock education. The ball is on you.
7. I DO NOT give buy or sell advice
8. COH (cash on hand); AH (after hours): RTH (regular trading hours)
$Aadi Biosciences (AADI.US)$ PR AH 12/...
68
33
8
$Lexicon Pharmaceuticals (LXRX.US)$
“New PDUFA date is expected to be December 20, 2024. Advisory Committee voted 11 to 3 that the benefits of Zynquista do not outweigh the risks in adults with T1D and CKD, noted November 1, 2024.”
nfa
“New PDUFA date is expected to be December 20, 2024. Advisory Committee voted 11 to 3 that the benefits of Zynquista do not outweigh the risks in adults with T1D and CKD, noted November 1, 2024.”
nfa
4
$Lexicon Pharmaceuticals (LXRX.US)$ its good news! continue up up
2
1
$Lexicon Pharmaceuticals (LXRX.US)$ interesting
1
$Lexicon Pharmaceuticals (LXRX.US)$ Lexicon Pharmaceuticals Says Company Has Made Strategic Decision To Eliminate Its Commercial Operations And Rationalize Resources Across All Functions In Order To Preserve Cash And Focus Its Resources On Advancing Promising Clinical Development Pipeline Following Regulatory Update From FDA; Efforts Expected To Reduce 2025 Operating Costs By $100M
This decision follows the receipt of a "deficiencies preclude discussion" letter from the U.S. Food and Drug A...
This decision follows the receipt of a "deficiencies preclude discussion" letter from the U.S. Food and Drug A...
No comment yet
Lnova : Oh wait fda rejected?
Lnova :
Jaguar8 OP Lnova : CRL
Lnova Jaguar8 OP : Gotcha. But Lex is discontinuing it? They are scrapping it?
Jaguar8 OP Lnova : I think that was their decision after the CRL.
View more comments...